Analyst Ratings For ChemoCentryx (NASDAQ:CCXI)
Today, JPMorgan Chase & Co. raised its price target on ChemoCentryx (NASDAQ:CCXI) to $16.00 per share.
Some recent analyst ratings include
- 8/8/2017-Cowen Reiterated Rating of Hold.
- 2/21/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
Recent Insider Trading Activity For ChemoCentryx (NASDAQ:CCXI)
ChemoCentryx (NASDAQ:CCXI) has insider ownership of 26.20% and institutional ownership of 48.55%.
- On 8/1/2017 Roger C Lucas, Director, sold 2,250 with an average share price of $10.07 per share and the total transaction amounting to $22,657.50.
- On 7/13/2017 Petrus Bekker, Insider, sold 76,013 with an average share price of $9.95 per share and the total transaction amounting to $756,329.35.
- On 7/12/2017 Petrus Bekker, Insider, sold 30,000 with an average share price of $9.98 per share and the total transaction amounting to $299,400.00.
- On 7/11/2017 Petrus Bekker, Insider, sold 30,000 with an average share price of $9.78 per share and the total transaction amounting to $293,400.00.
- On 7/10/2017 Petrus Bekker, Insider, sold 19,877 with an average share price of $9.30 per share and the total transaction amounting to $184,856.10.
- On 6/30/2017 Petrus Bekker, Insider, sold 65,509 with an average share price of $9.17 per share and the total transaction amounting to $600,717.53.
- On 5/1/2017 Roger C Lucas, Director, sold 4,000 with an average share price of $7.31 per share and the total transaction amounting to $29,240.00.
Recent Trading Activity for ChemoCentryx (NASDAQ:CCXI)
Shares of ChemoCentryx closed the previous trading session at with shares trading hands.
